Randomized trial of interferon‐ and ribavirin‐free ombitasvir/paritaprevir/ritonavir in treatment‐experienced hepatitis C virus–infected patients

Approximately 2 million Japanese individuals are infected with hepatitis C virus and are at risk for cirrhosis, end‐stage liver disease, and hepatocellular carcinoma. Patients in whom interferon (IFN)/ribavirin (RBV) therapy has failed remain at risk as effective therapeutic options are limited. Thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Chayama, Kazuaki, Notsumata, Kazuo, Kurosaki, Masayuki, Sato, Ken, Rodrigues, Lino, Setze, Carolyn, Badri, Prajakta, Pilot‐Matias, Tami, Vilchez, Regis A., Kumada, Hiromitsu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Viral Hepatitis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763364/
https://www.ncbi.nlm.nih.gov/pubmed/25644279
http://dx.doi.org/10.1002/hep.27705

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763364/
https://www.ncbi.nlm.nih.gov/pubmed/25644279
http://dx.doi.org/10.1002/hep.27705

Ejemplares similares